The Asia Pacific region is expected to grow at the fastest rate during the forecasted period. Reasons contributing
towards the fastest growth in the market are – increase spending by the government in order to improve
healthcare and R&D infrastructure in the areas of proteomics, genomics and NGS (next generation sequencing).
There has also been growing awareness in the growth market for early and effective diagnosis which will further
increase the growth in the market.
Competitive Insights
Key players in the development & commercialization of biochips include PerkinElmer, Inc.; Abbott Laboratories;
Bio-Rad Laboratories, Inc.; Fluidigm Corporation; Sigma-Aldrich Corporation; Agilent Technologies, Inc.; Thermo
Fisher Scientific, Inc. and GE Healthcare. In order to establish themselves in the untapped market, companies
are following various strategies including mergers & acquisitions, collaboration, vertical and horizontal
integration in regions/countries where they can see potential growth.
For example, PerkinElmer has successfully taken over Vanadis diagnostics which undergoes cell free DNA-based
noninvasive prenatal testing (NIPT) on the digital platform. This has extended PerkinElmer’s portfolio. Similar
strategies by other companies is expected to influence the market positively which will also bring
competitiveness in the market.
Market Segment:
Biochip Outlook, by Type (Revenue, USD Million, 2013 - 2024)
• DNA chips, by application
• Cancer diagnosis and treatment
• Gene expression
• Single Nucleotide Polymorphisms Genotyping
• Genomics.
• Drug discovery
• Agricultural biotechnology
• Others
• Lab-on-a-chip, by application
• Genomics
• IVD & POC
• Proteomics
• Drug discovery
• Others
• Protein chips, by application